Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline

Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.

Recce Pharmaceuticals has received an AUD $5.34 million cash refund under Australia’s 43.5% Research & Development Tax Incentive for eligible R&D activities undertaken in the 2025 financial year, providing non-dilutive funding to support its clinical and development programs. The company has also submitted a further claim and anticipates an additional refund of about AUD $3 million, which management says will help finance its Phase 3 clinical trial in Indonesia and other domestic studies, reinforcing its financial runway and capacity to advance its synthetic anti-infective portfolio in the highly competitive anti-infectives market.

The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.56 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.

More about Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd is an Australian biotechnology company developing a new class of synthetic anti-infectives to tackle antibiotic-resistant superbugs and serious infections caused by Gram-positive and Gram-negative bacteria, as well as viral pathogens. Its pipeline includes three patented broad-spectrum polymer anti-infectives—R327 for intravenous and topical use, R435 as an oral therapy, and R529 for viral infections—with global recognition from the World Health Organization and U.S. FDA incentives such as Fast Track designation and extended market exclusivity. The company owns its automated manufacturing facilities to support ongoing clinical trials and aims to address significant unmet medical needs in antimicrobial resistance.

Average Trading Volume: 136,260

Technical Sentiment Signal: Buy

Current Market Cap: A$189.4M

For a thorough assessment of RCE stock, go to TipRanks’ Stock Analysis page.